Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc, Univ KingstonfiledCriticalPentech Pharmaceuticals Inc
Priority to UY26747ApriorityCriticalpatent/UY26747A1/en
Publication of UY26747A1publicationCriticalpatent/UY26747A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
La impotencia psicogénica o disfunción eréctil puede identificarse en pacientes masculinos psicogénicos y puede eliminarse, sin efectos laterales importantes no deseados, mediante la administración sublingual de formas de dosis de apomorfina que contienen de aproximadamente 2.5 a aproximadamente 10 miligramos de apomorfina y que se disuelven dentro de un período de aproximadamente 2 a aproximadamente 5 minutos.Psychogenic impotence or erectile dysfunction can be identified in psychogenic male patients and can be eliminated, without significant unwanted side effects, by sublingual administration of dosage forms of apomorphine that contain about 2.5 to about 10 milligrams of apomorphine and that dissolve within a period of about 2 to about 5 minutes.
UY26747A2001-06-042001-06-04
DOSAGE FORMS AND METHODS TO IMPROVE MALE ERECTILE DYSFUNCTION
UY26747A1
(en)
APPLICATION OF A COMBINATION CONTAINING A NON-NUCLEOSIDE INHIBITOR REVERSE TRANSCRIPTASIS (NNIOT) IN COMBINATION WITH A CYTOCHROME P450 INHIBITOR SO AS PROTEASE INHIBITORS